The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

This new drug capivasertib is a targeted therapy. It works in a new way, blocking the activity of a protein molecule called AKT which drives cancer growth. Scientists started working on the drug's ...

which was involved in the drug development research for capivasertib, said it “strongly welcomed” the decision. Nicholas Turner, professor of molecular oncology at the ICR and consultant ...

She says that capivasertib, which she has been able to access via private healthcare, has not only extended her life but improved its quality with fewer side effects than previous medications.